Updates and Statements

07.28.2021

Pfizer and BioNTech Share Detailed Update to the Results from 6 Month Safety and Efficacy Data Analysis of Landmark COVID-19 Vaccine Study

07.16.2021

U.S. FDA Grants Priority Review for the Biologics License Application for Pfizer-BioNTech COVID-19 Vaccine

07.16.2021

Pfizer Issues A Voluntary Nationwide Recall for Twelve Lots of CHANTIX® (varenicline) Tablets Due to N-Nitroso Varenicline Content

07.08.2021

Newly Published Expert Opinion Article Details Evidence for Classifying Aging Immune System as a High-Risk Condition for Pneumococcal Vaccine Policy

07.08.2021

Pfizer and BioNTech Provide Update on Booster Program in Light of the Delta-Variant

06.11.2021

XELJANZ® Safety Review Recommendation Issued in the European Union

05.28.2021

Pfizer Colleagues to Mentor Veterans in Transition to Civilian Life

05.11.2021

Pfizer’s Novel Prediction Model, Derived from Machine Learning, Shows Robust Performance for Identifying Heart Failure Patients At-Risk for Wild-Type Transthyretin Amyloid Cardiomyopathy, a Rare and Life-Threatening Condition

05.04.2021

Hospira Issues A Voluntary Nationwide Recall for One Lot of Sterile Water for Injection, USP, Due to the Potential Presence of Visible Particulate

05.04.2021

Hospira Issues A Voluntary Nationwide Recall for One Lot of 0.5% Bupivacaine Hydrochloride Injection, USP and One Lot of 1% Lidocaine HCl Injection, USP Due to Mislabeling

04.22.2021

Pfizer Announces 2021 Shareholder Meeting Results

04.09.2021

Pfizer and BioNTech Request Regulatory Agencies Expand Emergency Use of Their COVID-19 Vaccine to Adolescents